Replacement of Valsartan and Candesartan by Telmisartan in Hypertensive Patients With Type 2 Diabetes

Metabolic and antiatherogenic consequences

  1. Yoshitaka Miura, MD, PHD,
  2. Naoki Yamamoto, MD,
  3. Shin Tsunekawa, MD,
  4. Seiko Taguchi, MD,
  5. Yoko Eguchi, MD, PHD,
  6. Nobuaki Ozaki, MD, PHD and
  7. Yutaka Oiso, MD, PHD
  1. From the Department of Endocrinology and Diabetology, Nagoya University School of Medicine, Nagoya, Japan
  1. Address correspondence to Yoshitaka Miura, MD, PhD, Department of Endocrinology and Diabetology, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. E-mail: ymiura64{at}med.nagoya-u.ac.jp

Angiotensin II type 1 receptor blockers (ARBs) are widely used in the treatment of hypertension and have been shown to restore impaired intracellular insulin signaling and reduce the incidence of type 2 diabetes (1–3). Telmisartan has a unique property that activates peroxisome proliferator-activated receptor-γ (PPAR-γ) (4–6). We studied the effect of this unique property of telmisartan on insulin resistance and circulating levels of adiponectin and highly sensitive C-reactive protein (hs-CRP) in hypertensive patients with type 2 diabetes.

The study comprised 18 participants with hypertensive type 2 diabetes (9 men and 9 women) aged 36–79 years (64 ± 12, …

| Table of Contents